Discovery of an Allosteric Agonist for Schizophrenia Risk Gene GPR52 with Antipsychotic Activity

被引：0
|
作者：
Murphy, Ryan E. [1 ]
Felsing, Daniel E. [1 ]
Dvorak, Nolan M. [1 ]
Laezza, Fernanda [1 ]
Cunningham, Kathryn A. [1 ]
Allen, John A. [1 ]
机构：
[1] Univ Texas Med Branch, Houston, TX USA
来源：
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS | 2023年 / 385卷
关键词：
D O I：
10.1124/jpet.122.278870
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
537
引用
收藏
页数：1
相关论文
共 47 条
  • [31] Structure-Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469
    Christiansen, Elisabeth
    Due-Hansen, Maria E.
    Urban, Christian
    Merten, Nicole
    Pfleiderer, Michael
    Karlsen, Kasper K.
    Rasmussen, Sanne S.
    Steensgaard, Mette
    Hamacher, Alexandra
    Schmidt, Johannes
    Drewke, Christel
    Petersen, Rasmus Koefoed
    Kristiansen, Karsten
    Ullrich, Susanne
    Kostenis, Evi
    Kassack, Matthias U.
    Ulven, Trond
    ACS MEDICINAL CHEMISTRY LETTERS, 2010, 1 (07): : 345 - 349
  • [32] Effects of ABCB1 gene polymorphisms on autonomic nervous system activity during atypical antipsychotic treatment in schizophrenia
    Hattori, Saki
    Suda, Akira
    Kishida, Ikuko
    Miyauchi, Masatoshi
    Shiraishi, Yohko
    Fujibayashi, Mami
    Tsujita, Natsuki
    Ishii, Chie
    Ishii, Norio
    Moritani, Toshio
    Taguri, Masataka
    Hirayasu, Yoshio
    BMC PSYCHIATRY, 2018, 18
  • [33] Effects of ABCB1 gene polymorphisms on autonomic nervous system activity during atypical antipsychotic treatment in schizophrenia
    Saki Hattori
    Akira Suda
    Ikuko Kishida
    Masatoshi Miyauchi
    Yohko Shiraishi
    Mami Fujibayashi
    Natsuki Tsujita
    Chie Ishii
    Norio Ishii
    Toshio Moritani
    Masataka Taguri
    Yoshio Hirayasu
    BMC Psychiatry, 18
  • [34] Schizophrenia risk gene CAV1 is both pro-psychotic and required for atypical antipsychotic drug actions in vivo
    J A Allen
    P N Yadav
    V Setola
    M Farrell
    B L Roth
    Translational Psychiatry, 2011, 1 : e33 - e33
  • [35] Schizophrenia risk gene CAV1 is both pro-psychotic and required for atypical antipsychotic drug actions in vivo
    Allen, J. A.
    Yadav, P. N.
    Setola, V.
    Farrell, M.
    Roth, B. L.
    TRANSLATIONAL PSYCHIATRY, 2011, 1 : e33 - e33
  • [36] Orphan receptor-GPR52 inverse agonist efficacy in ameliorating chronic stress-related deficits in reward motivation and phasic accumbal dopamine activity in mice
    Zhang, Chenfeng
    Kukel'ova, Diana
    Sigrist, Hannes
    Hengerer, Bastian
    Kratzer, Ramona F.
    Mracek, Philipp
    Omrani, Azar
    von Heimendahl, Moritz
    Pryce, Christopher R.
    TRANSLATIONAL PSYCHIATRY, 2024, 14 (01):
  • [37] A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity
    Galici, R
    Echemendia, NG
    Rodriguez, AL
    Conn, PJ
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (03): : 1181 - 1187
  • [38] Comparison of the mGlu5 receptor positive allosteric modulator ADX47273 and the mGlu2/3 receptor agonist LY354740 in tests for antipsychotic-like activity
    Schlumberger, Chantal
    Pietraszek, Malgorzata
    Gravius, Andreas
    Klein, Kai-Uwe
    Greco, Sergio
    More, Lorenzo
    Danysz, Wojciech
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2009, 623 (1-3) : 73 - 83
  • [39] Schizophrenia Risk Associated DRD2 Single Nucleotide Polymorphisms Impact Antipsychotic Drug Response and Its Gene Expression in Postmortem Human Brains
    Zhang, Fengyu
    Birnbaum, Rebecca
    Apud, Jose
    Radulescu, Eugenia
    Bigos, Kristin
    Chen, Qiang
    Hyde, Thomas
    Kleinman, Joel
    Weinberger, Daniel
    NEUROPSYCHOPHARMACOLOGY, 2014, 39 : S429 - S430
  • [40] The obesity risk gene FTO influences body mass in chronic schizophrenia but not initial antipsychotic drug-induced weight gain in first-episode patients
    Reynolds, Gavin P.
    Yevtushenko, Olga O.
    Gordon, Sarah
    Arranz, Belen
    San, Luis
    Cooper, Stephen J.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2013, 16 (06): : 1421 - 1425
12345